GLX-100 / Glycologix - LARVOL DELTA

Glycologix to Present Phase 1b Clinical Trial Data for GLX-100 at American Urological Association (AUA) 2025 Annual Meeting (Businesswire) - "Glycologix, Inc...announced that clinical results from its multi-center, Phase 1b study of GLX-100 in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) will be presented at the American Urological Association (AUA) 2025 Annual Meeting in Las Vegas, Nevada....Based on the data from this Phase 1b trial, Glycologix is planning a phase 2b study with GLX-100."

New P2b trial • P1 data • Interstitial Cystitis • Urology

A Phase 1b, First-in-Human, Open-label, Single-Arm Study Evaluating the Safety and Efficacy of GLX-100, a Novel Synthetic Glycosaminoglycan Replacement Therapy in Subjects with Interstitial Cystitis/Bladder Pain Syndrome (AUA 2025) - "GLX-100 was well tolerated and shows clinically meaningful treatment outcomes, including reduction in bladder pain, improvements in O'Leary-Sant ICSI/ICPI scores and the GRA. A randomized, placebo-controlled Phase 2b multicenter study is planned as the next step for this novel therapy for IC/BPS."

Clinical • P1 data • Infectious Disease • Influenza • Interstitial Cystitis • Musculoskeletal Pain • Nephrology • Pain • Respiratory Diseases

Development of a unique crosslinked glycosaminoglycan for soft tissue repair: Treatment of interstitial cystitis/bladder pain syndrome. (PubMed, PLoS One) - "A representative material (GLX-100) demonstrated durable restoration of bladder impermeability in a gold standard animal model of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)...A set of agents have been used, demonstrating the preparation of a family of SuperGAGs with diverse capabilities. We can optimize polymer properties, adjust adherence to various tissues, add reporters, and engage the biochemistry of surrounding tissues with peptides and other bioactives."

Journal • Interstitial Cystitis • Musculoskeletal Pain • Pain

Safety and Preliminary Effectiveness of GLX-100 in Participants With Interstitial Cystitis/Painful Bladder Syndrome. (ANZCTR) - P1 | N=40 | Recruiting | Sponsor: Glycologix Australia PTY LTD | Not yet recruiting ➔ Recruiting | Initiation date: Oct 2023

Enrollment open • Trial initiation date • Interstitial Cystitis • Pain

Safety and Preliminary Effectiveness of GLX-100 in Participants With Interstitial Cystitis/Painful Bladder Syndrome. (ANZCTR) - P1 | N=40 | Not yet recruiting | Sponsor: Glycologix Australia PTY LTD

New P1 trial • Interstitial Cystitis • Pain